Navigation Links
Families of SMA Releases Newsletter Describing the Scientific Strategy Behind Antisense Drugs for Spinal Muscular Atrophy
Date:12/9/2013

Elk Grove Village, IL (PRWEB) December 09, 2013

Families of SMA has released a new edition of the Compass Newsletter, a publication dedicated to research updates. This newsletter was produced in a collaboration between Families of SMA, Biogen Idec, and Isis Pharmaceuticals. It describes the scientific strategy behind Antisense Drugs. It also provides updates on the ongoing research and clinical trials for this class of SMA drugs.

This edition of Compass, includes information about:

-The ABC's of Antisense Drugs

-ISIS-SMNRX Program Update on Ongoing and Future Clinical Trials

-FSMA Grant Award to Dr. Adrian Krainer at CSHL to Assess Influence of Backbone Chemistry on Antisense Drugs

-FSMA Grant Award to Drs. Arthur Burghes and Christian Lorson for Novel Antisense Therapies

-Report on New Data from the Completed Phase I Study Evaluating the Safety of Isis-SMNRX

Antisense drugs are small snippets of synthetic genetic material that bind to RNA (short for ribonucleic acid). The main factor driving where the antisense drug binds to the RNA is the nucleic acid sequence used. Nucleic acids consist of a chain of linked units called nucleotides. Antisense drugs are typically 12-21 nucleotides that are chemically modified to bring about the appropriate drug response.

How does the antisense approach work for SMA?
SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene. The SMN1 gene produces most of the SMN protein, which is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle function. The severity of SMA is correlated with the amount of SMN protein in the cell. A second closely related back-up gene called SMN2 exists that normally produces a truncated, low-functioning form of SMN protein. Antisense therapy could be used to change the functioning of the SMN2 gene by utilizing alternative RNA splicing. Alternative splicing is a normal mechanism that the cell uses to produce different, but closely related proteins from a single gene.

About Families of SMA
Families of SMA has awarded four new drug discovery projects since the start of 2013. The research progress provides hope that one day we will live in a world without SMA. There are now 15 new SMA drug programs in development, including 4 in clinical trials. This pipeline has expanded from just 4 programs 5 years ago. Families of SMA has funded over half of all the ongoing drug programs for SMA. The FSMA research approach funds programs at early stages, and then partners with companies to take them through clinical trials. Supporting multiple programs gives different approaches for a SMA therapy, which increases the chances of success and accelerates the timeline to a treatment and cure.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11401483.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Super-Sod is Donating their Doc's Raised Garden Kits to Families and Community Gardens
2. Families Grateful for At-work Access to Youth Cardiac, Concussion Screenings
3. Narconon International Publishes Indispensible Guide for Families Dealing with Addiction
4. IBT’s Top Ten Holiday Tips Minimize Challenges for Children with Autism and Their Families
5. A New Website for Families to Turn: New Health and Wellness Promotion Website Launched by Family Voices
6. YMCA Thanksgiving Dinner Supports Families in Need
7. 1-800-HOMECARE Comments on Recent Nursing Home Theft That Strikes Seniors andFamilies
8. STAR Center Raising Funds for Special Needs Children of Military Families
9. Princeton study: Military children and their families remain an invisible subculture
10. Researchers at Pace University Explore the Lived Experiences of Families Members That Have the Possible Risk of Genetic Mutations That Cause Sudden Cardiac Death
11. Families, Businesses & Special Needs Children Rally to Support America's Special Kidz (A.S.K.)'s First Fundraiser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel ... Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety of ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology: